Karyopharm Therapeutics (NASDAQ:KPTI) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.
According to Zacks, “Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the discovery and development of drugs for the treatment of cancer and other major diseases. It serves the healthcare industry throughout the United States. Karyopharm Therapeutics, Inc. is based in United States. “
Several other research firms also recently issued reports on KPTI. Canaccord Genuity boosted their price objective on Karyopharm Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a report on Monday, March 12th. HC Wainwright boosted their price objective on Karyopharm Therapeutics to $26.00 and gave the company a “buy” rating in a report on Thursday, March 15th. Cantor Fitzgerald set a $18.00 price objective on Karyopharm Therapeutics and gave the company a “buy” rating in a report on Thursday, March 15th. JPMorgan Chase & Co. reiterated an “overweight” rating and issued a $19.00 price objective (up previously from $18.00) on shares of Karyopharm Therapeutics in a report on Friday, March 16th. Finally, Robert W. Baird set a $22.00 price objective on Karyopharm Therapeutics and gave the company a “buy” rating in a report on Thursday, March 15th. Two research analysts have rated the stock with a sell rating and ten have issued a buy rating to the company’s stock. Karyopharm Therapeutics presently has a consensus rating of “Buy” and an average target price of $19.60.
KPTI stock opened at $15.66 on Wednesday. Karyopharm Therapeutics has a 12 month low of $7.48 and a 12 month high of $18.00. The company has a market capitalization of $794.94, a price-to-earnings ratio of -5.59 and a beta of 3.62.
Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings results on Thursday, March 15th. The company reported ($0.80) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.66) by ($0.14). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 89.62%. The business had revenue of $1.53 million during the quarter, compared to analyst estimates of $2.26 million. During the same period last year, the company earned ($0.65) EPS. The business’s revenue for the quarter was up 3163.8% on a year-over-year basis. research analysts predict that Karyopharm Therapeutics will post -2.65 earnings per share for the current year.
In other Karyopharm Therapeutics news, EVP Christopher Brett Primiano sold 2,500 shares of the company’s stock in a transaction dated Friday, February 16th. The stock was sold at an average price of $15.01, for a total transaction of $37,525.00. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Michael Kauffman sold 10,000 shares of the company’s stock in a transaction dated Thursday, January 18th. The stock was sold at an average price of $10.09, for a total value of $100,900.00. Following the sale, the chief executive officer now owns 522,143 shares in the company, valued at approximately $5,268,422.87. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 69,000 shares of company stock worth $928,625. 14.71% of the stock is owned by company insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of the business. Schwab Charles Investment Management Inc. lifted its position in Karyopharm Therapeutics by 21.0% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 140,360 shares of the company’s stock worth $1,542,000 after acquiring an additional 24,324 shares during the period. Dimensional Fund Advisors LP increased its stake in Karyopharm Therapeutics by 17.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 323,671 shares of the company’s stock valued at $2,930,000 after purchasing an additional 47,699 shares in the last quarter. State Street Corp increased its stake in Karyopharm Therapeutics by 10.1% in the 2nd quarter. State Street Corp now owns 511,920 shares of the company’s stock valued at $4,631,000 after purchasing an additional 47,127 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Karyopharm Therapeutics by 753.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 307,200 shares of the company’s stock valued at $3,342,000 after purchasing an additional 271,208 shares in the last quarter. Finally, Nationwide Fund Advisors increased its stake in Karyopharm Therapeutics by 396.0% in the 3rd quarter. Nationwide Fund Advisors now owns 105,664 shares of the company’s stock valued at $1,160,000 after purchasing an additional 84,362 shares in the last quarter. Institutional investors own 62.60% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Zacks Investment Research Lowers Karyopharm Therapeutics (KPTI) to Sell” was first posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark and copyright laws. The original version of this article can be accessed at https://www.thelincolnianonline.com/2018/03/21/zacks-investment-research-lowers-karyopharm-therapeutics-kpti-to-sell.html.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.